Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Finardi G, Fratino P
IRCCS Maugeri Foundation Hospital, Section of Internal Medicine, Diabetes Centre, Pavia, Italy.
Diabet Med. 2001 Jul;18(7):589-94. doi: 10.1046/j.1464-5491.2001.00536.x.
We investigated whether in Type 2 diabetic patients lipoprotein(a) (Lp(a)) levels and apolipoprotein(a) (apo(a)) polymorphism are associated with angiographically documented coronary artery disease (CAD). We also examined whether there are differences in the distributions of Lp(a) levels and apo(a) phenotypes between CAD patients with and without diabetes.
A hundred and seven diabetic patients with CAD, 274 diabetic patients without CAD, 201 non-diabetic patients with CAD, and 358 controls were enrolled.
Diabetic patients with CAD showed Lp(a) levels (21.2 +/- 17.7 vs. 15.1 +/- 17.8 mg/dl; P = 0.0018) and a percentage of subjects with at least one apo(a) isoform of low molecular weight (MW) (67.2% vs. 27.7%; P = 0.0000) significantly greater than diabetic patients without CAD. Multivariate analysis showed that in diabetic patients Lp(a) levels and apo(a) phenotypes were significantly associated with CAD; odds ratios (ORs) of high Lp(a) levels for CAD were 2.17 (1.28-3.66), while ORs of the presence of at least one apo(a) isoform of low MW were 5.35 (3.30-8.60). Lp(a) levels (30.2 +/- 23.7 vs. 21.2 +/- 17.7 mg/dl; P = 0.0005) and the percentage of subjects with at least one apo(a) isoform of low MW (87.0% vs. 67.2%; P = 0.0001) were significantly higher in CAD patients without than in those with diabetes.
Our data suggest that Lp(a) levels and apo(a) phenotypes are independently associated with CAD in Type 2 diabetic patients; thus both these parameters may be helpful in selecting diabetic subjects at high genetic cardiovascular risk. However, Lp(a) levels and apo(a) polymorphism seem to be cardiovascular risk factors less important in diabetic than in non-diabetic subjects. Diabet. Med. 18, 589-594 (2001)
我们研究了2型糖尿病患者的脂蛋白(a) [Lp(a)]水平和载脂蛋白(a) [apo(a)]多态性是否与血管造影证实的冠状动脉疾病(CAD)相关。我们还检查了患有和未患有糖尿病的CAD患者之间Lp(a)水平和apo(a)表型分布是否存在差异。
招募了107例患有CAD的糖尿病患者、274例未患有CAD的糖尿病患者、201例未患有糖尿病的CAD患者和358例对照。
患有CAD的糖尿病患者的Lp(a)水平(21.2±17.7对15.1±17.8mg/dl;P = 0.0018)以及至少有一种低分子量(MW)apo(a)异构体的受试者百分比(67.2%对27.7%;P = 0.0000)显著高于未患有CAD的糖尿病患者。多变量分析显示,在糖尿病患者中,Lp(a)水平和apo(a)表型与CAD显著相关;CAD患者中高Lp(a)水平的比值比(OR)为2.17(1.28 - 3.66),而至少有一种低MW apo(a)异构体存在的OR为5.35(3.30 - 8.60)。未患有糖尿病的CAD患者的Lp(a)水平(30.2±23.7对21.2±17.7mg/dl;P = 0.0005)以及至少有一种低MW apo(a)异构体的受试者百分比(87.0%对67.2%;P = 0.0001)显著高于患有糖尿病的CAD患者。
我们的数据表明,Lp(a)水平和apo(a)表型与2型糖尿病患者的CAD独立相关;因此,这两个参数可能有助于筛选出具有高遗传心血管风险的糖尿病患者。然而,Lp(a)水平和apo(a)多态性似乎是糖尿病患者中比非糖尿病患者不太重要的心血管危险因素。《糖尿病医学》18, 589 - 594 (2001)